Table Graph
   

Immunosuppressants drugs - versus standard of care - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.81 [0.67, 0.98]< 16%14 studies (14/-)98.6 %some concernlow moderatecrucial-
death or transfer to ICU 0.93 [0.87, 0.99]< 10%1 study (-/1)98.6 %NAnot evaluable crucial-
deaths 0.78 [0.69, 0.88]< 115%24 studies (22/2)100.0 %moderatecritical moderatecrucial-
deaths (time to event analysis only) 0.68 [0.41, 1.13]< 10%2 studies (2/-)93.2 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.85 [0.59, 1.22]< 10%4 studies (4/-)81.3 %some concernnot evaluable moderateimportant-
clinical improvement 1.68 [1.34, 2.11]> 10%3 studies (3/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.86 [1.20, 2.87]> 10%1 study (1/-)99.7 %NAnot evaluable important-
death or ventilation 0.87 [0.80, 0.94]< 113%6 studies (6/-)100.0 %some concernnot evaluable moderateimportant-
hospital discharge 23.94 [10.77, 53.20]> 10%1 study (-/1)100.0 %NAnot evaluable important-
mechanical ventilation 0.88 [0.76, 1.01]< 10%5 studies (5/-)96.2 %some concernnot evaluable moderateimportant-
ICU admission 0.56 [0.20, 1.63]< 186%5 studies (3/2)85.5 %moderatenot evaluable moderatenon important-
recovery 0.64 [0.14, 2.92]> 10%1 study (1/-)28.3 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 1.27 [0.70, 2.32]< 10%4 studies (4/-)21.9 %some concernnot evaluable moderateimportant-
acute kidney injury 0.43 [0.14, 1.34]< 10%1 study (-/1)92.7 %NAnot evaluable non important-
adverse events 2.47 [1.00, 6.10]< 172%3 studies (3/-)2.5 %some concernnot evaluable moderatenon important-
arrhythmia 0.16 [0.03, 0.90]< 10%1 study (-/1)98.1 %NAnot evaluable non important-
elevated liver enzymes 0.52 [0.18, 1.51]< 10%1 study (-/1)88.5 %NAnot evaluable non important-
Myocardial infarction 0.87 [0.19, 3.92]< 10%1 study (-/1)57.2 %NAnot evaluable non important-
venous thromboembolism 5.23 [0.42, 65.62]< 10%1 study (-/1)10.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons